Literature DB >> 24366507

Outcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States.

Shannon L Maude1, Julie C Fitzgerald, Brian T Fisher, Yimei Li, Yuan-Shung Huang, Kari Torp, Alix E Seif, Marko Kavcic, Dana M Walker, Kateri H Leckerman, Todd J Kilbaugh, Susan R Rheingold, Lillian Sung, Theoklis E Zaoutis, Robert A Berg, Vinay M Nadkarni, Neal J Thomas, Richard Aplenc.   

Abstract

OBJECTIVE: Children with acute myeloid leukemia are at risk for sepsis and organ failure. Outcomes associated with intensive care support have not been studied in a large pediatric acute myeloid leukemia population. Our objective was to determine hospital mortality of pediatric acute myeloid leukemia patients requiring intensive care.
DESIGN: Retrospective cohort study of children hospitalized between 1999 and 2010. Use of intensive care was defined by utilization of specific procedures and resources. The primary endpoint was hospital mortality.
SETTING: Forty-three children's hospitals contributing data to the Pediatric Health Information System database. PATIENTS: Patients who are newly diagnosed with acute myeloid leukemia and who are 28 days through 18 years old (n = 1,673) hospitalized any time from initial diagnosis through 9 months following diagnosis or until stem cell transplant. A reference cohort of all nononcology pediatric admissions using the same intensive care resources in the same time period (n = 242,192 admissions) was also studied.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: One-third of pediatric patients with acute myeloid leukemia (553 of 1,673) required intensive care during a hospitalization within 9 months of diagnosis. Among intensive care admissions, mortality was higher in the acute myeloid leukemia cohort compared with the nononcology cohort (18.6% vs 6.5%; odds ratio, 3.23; 95% CI, 2.64-3.94). However, when sepsis was present, mortality was not significantly different between cohorts (21.9% vs 19.5%; odds ratio, 1.17; 95% CI, 0.89-1.53). Mortality was consistently higher for each type of organ failure in the acute myeloid leukemia cohort versus the nononcology cohort; however, mortality did not exceed 40% unless there were four or more organ failures in the admission. Mortality for admissions requiring intensive care decreased over time for both cohorts (23.7% in 1999-2003 vs 16.4% in 2004-2010 in the acute myeloid leukemia cohort, p = 0.0367; and 7.5% in 1999-2003 vs 6.5% in 2004-2010 in the nononcology cohort, p < 0.0001).
CONCLUSIONS: Pediatric patients with acute myeloid leukemia frequently required intensive care resources, with mortality rates substantially lower than previously reported. Mortality also decreased over the time studied. Pediatric acute myeloid leukemia patients with sepsis who required intensive care had a mortality comparable to children without oncologic diagnoses; however, overall mortality and mortality for each category of organ failure studied was higher for the acute myeloid leukemia cohort compared with the nononcology cohort.

Entities:  

Mesh:

Year:  2014        PMID: 24366507      PMCID: PMC4407366          DOI: 10.1097/PCC.0000000000000042

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  46 in total

1.  Inpatient care for septicemia or sepsis: a challenge for patients and hospitals.

Authors:  Margaret Jean Hall; Sonja N Williams; Carol J DeFrances; Aleksandr Golosinskiy
Journal:  NCHS Data Brief       Date:  2011-06

2.  Federating clinical data from six pediatric hospitals: process and initial results from the PHIS+ Consortium.

Authors:  Scott P Narus; Rajendu Srivastava; Ramkiran Gouripeddi; Oren E Livne; Peter Mo; Jonathan P Bickel; David de Regt; Joseph W Hales; Eric Kirkendall; Richard L Stepanek; Jamie Toth; Ron Keren
Journal:  AMIA Annu Symp Proc       Date:  2011-10-22

3.  Prognostic factors in pediatric cancer patients admitted to the pediatric intensive care unit.

Authors:  Oguz Dursun; Volkan Hazar; Gulsun Tezcan Karasu; Vedat Uygun; Ozgur Tosun; Akif Yesilipek
Journal:  J Pediatr Hematol Oncol       Date:  2009-07       Impact factor: 1.289

4.  Early changes in SOFA score as a prognostic factor in pediatric oncology patients requiring mechanical ventilatory support.

Authors:  Eun Ju Ha; Seonguk Kim; Hyun Seung Jin; Keun Wook Bae; Ho Joon Lim; Jong Jin Seo; Seong Jong Park
Journal:  J Pediatr Hematol Oncol       Date:  2010-11       Impact factor: 1.289

5.  The epidemiology of sepsis in the United States from 1979 through 2000.

Authors:  Greg S Martin; David M Mannino; Stephanie Eaton; Marc Moss
Journal:  N Engl J Med       Date:  2003-04-17       Impact factor: 91.245

6.  Long term survival in children with acute leukaemia and complications requiring mechanical ventilation.

Authors:  Daniel Steinbach; Bernhard Wilhelm; Hans-Rudolf Kiermaier; Ursula Creutzig; Martin Schrappe; Martin Zimmermann; Klaus-Michael Debatin; Bernd Gruhn; Arend von Stackelberg; Heribert Jürgens; Brigitte Strahm; Dirk Reinhardt; Anja Möricke
Journal:  Arch Dis Child       Date:  2011-06-29       Impact factor: 3.791

7.  Early and treatment-related deaths in childhood acute myeloid leukaemia in the Nordic countries: 1984-2003.

Authors:  Lene Molgaard-Hansen; Merja Möttönen; Heidi Glosli; Guðmundur K Jónmundsson; Jonas Abrahamsson; Henrik Hasle
Journal:  Br J Haematol       Date:  2010-10-19       Impact factor: 6.998

8.  Indications for admission, treatment and improved outcome of paediatric haematology/oncology patients admitted to a tertiary paediatric ICU.

Authors:  C Owens; D Mannion; A O'Marcaigh; M Waldron; K Butler; A O'Meara
Journal:  Ir J Med Sci       Date:  2010-11-10       Impact factor: 1.568

9.  MultiCenter outcome of pediatric oncology patients requiring intensive care.

Authors:  Heidi J Dalton; Anthony D Slonim; Murray M Pollack
Journal:  Pediatr Hematol Oncol       Date:  2003-12       Impact factor: 1.969

10.  Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial.

Authors:  Brenda E S Gibson; David K H Webb; Andrew J Howman; Siebold S N De Graaf; Christine J Harrison; Keith Wheatley
Journal:  Br J Haematol       Date:  2011-09-09       Impact factor: 6.998

View more
  25 in total

1.  Association of weekend admission with hospital length of stay, time to chemotherapy, and risk for respiratory failure in pediatric patients with newly diagnosed leukemia at freestanding US children's hospitals.

Authors:  Elizabeth K Goodman; Anne F Reilly; Brian T Fisher; Julie Fitzgerald; Yimei Li; Alix E Seif; Yuan-Shung Huang; Rochelle Bagatell; Richard Aplenc
Journal:  JAMA Pediatr       Date:  2014-10       Impact factor: 16.193

2.  Cost-effectiveness of levofloxacin prophylaxis against bacterial infection in pediatric patients with acute myeloid leukemia.

Authors:  Meghan McCormick; Erika Friehling; Ramasubramanian Kalpatthi; Nalyn Siripong; Kenneth Smith
Journal:  Pediatr Blood Cancer       Date:  2020-07-25       Impact factor: 3.167

3.  Hospital-Level Variability in Broad-Spectrum Antibiotic Use for Children With Acute Leukemia Undergoing Hematopoietic Cell Transplantation.

Authors:  Caitlin W Elgarten; Staci D Arnold; Yimei Li; Yuan-Shung V Huang; Marcie L Riches; Jeffrey S Gerber; Richard Aplenc; Wael Saber; Brian T Fisher
Journal:  Infect Control Hosp Epidemiol       Date:  2018-05-08       Impact factor: 3.254

Review 4.  The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy.

Authors:  Felipe Bedoya; Matthew J Frigault; Marcela V Maus
Journal:  Mol Ther       Date:  2017-02-01       Impact factor: 11.454

5.  Comparable on-therapy mortality and supportive care requirements in Black and White patients following initial induction for pediatric acute myeloid leukemia.

Authors:  Yimei Li; Joanna G Newton; Kelly D Getz; Yuan-Shung Huang; Alix E Seif; Brian T Fisher; Richard Aplenc; Lena E Winestone
Journal:  Pediatr Blood Cancer       Date:  2018-12-26       Impact factor: 3.167

6.  Volume-Outcome Relationships in Pediatric Acute Lymphoblastic Leukemia: Association Between Hospital Pediatric and Pediatric Oncology Volume With Mortality and Intensive Care Resources During Initial Therapy.

Authors:  Jennifer J Wilkes; Sean Hennessy; Rui Xiao; Susan Rheingold; Alix E Seif; Yuan-Shung Huang; Neika Vendetti; Yimei Li; Rochelle Bagatell; Richard Aplenc; Brian T Fisher
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-05-04

7.  Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment.

Authors:  Lena E Winestone; Kelly D Getz; Pooja Rao; Yimei Li; Matt Hall; Yuan-Shung V Huang; Alix E Seif; Brian T Fisher; Richard Aplenc
Journal:  Leuk Lymphoma       Date:  2019-02-07

8.  Supportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at free-standing paediatric hospitals in the United States.

Authors:  Elizabeth G Salazar; Yimei Li; Brian T Fisher; Susan R Rheingold; Julie Fitzgerald; Alix E Seif; Yuan-Shung Huang; Rochelle Bagatell; Richard Aplenc
Journal:  Br J Haematol       Date:  2016-05-10       Impact factor: 6.998

9.  Hospital Variation in Intensive Care Resource Utilization and Mortality in Newly Diagnosed Pediatric Leukemia.

Authors:  Julie C Fitzgerald; Yimei Li; Brian T Fisher; Yuan-Shung Huang; Tamara P Miller; Rochelle Bagatell; Alix E Seif; Richard Aplenc; Neal J Thomas
Journal:  Pediatr Crit Care Med       Date:  2018-06       Impact factor: 3.624

10.  Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries.

Authors:  Matt S Zinter; Brent R Logan; Caitrin Fretham; Anil Sapru; Allistair Abraham; Mahmoud D Aljurf; Staci D Arnold; Andrew Artz; Jeffery J Auletta; Saurabh Chhabra; Edward Copelan; Christine Duncan; Robert P Gale; Eva Guinan; Peiman Hematti; Amy K Keating; David I Marks; Richard Olsson; Bipin N Savani; Celalettin Ustun; Kirsten M Williams; Marcelo C Pasquini; Christopher C Dvorak
Journal:  Biol Blood Marrow Transplant       Date:  2019-09-26       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.